Last $10.05 USD
Change Today -0.093 / -0.92%
Volume 476.7K
ADXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 11:51 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

advaxis inc (ADXS) Snapshot

Open
$9.66
Previous Close
$10.14
Day High
$10.25
Day Low
$9.60
52 Week High
01/20/15 - $13.74
52 Week Low
04/15/14 - $2.46
Market Cap
236.9M
Average Volume 10 Days
3.5M
EPS TTM
$-0.97
Shares Outstanding
23.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADVAXIS INC (ADXS)

Related News

No related news articles were found.

advaxis inc (ADXS) Related Businessweek News

No Related Businessweek News Found

advaxis inc (ADXS) Details

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate designed to target the PSA antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate for the treatment of Her2 expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has a clinical trial collaboration with MedImmune, LLC to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV, a cancer immunotherapy vaccine to treat patients with cervical cancer, and HPV-associated head and neck cancer. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

20 Employees
Last Reported Date: 01/6/15
Founded in 2002

advaxis inc (ADXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.

advaxis inc (ADXS) Key Developments

Advaxis Announces FDA Acceptance of its Investigational New Drug Application to Commence First-in-Human Clinical Trials of ADXS-HER2

Advaxis, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. The clinical trial, which will be the first-in-human study of Advaxis's lead Lm-LLO immunotherapy product for HER2 expressing cancers, is expected to begin patient enrollment in the first half of 2015. In May 2014 [2], Advaxis was granted orphan drug designation by the FDA for ADXS-HER2 in osteosarcoma. The Phase 1 clinical study is designed to evaluate the safety and tolerability of ADXS-HER2 as a monotherapy in patients with metastatic HER2 expressing solid tumors such as breast, gastric, esophageal, and osteosarcoma. Results from the study will be used to determine the future clinical development program of ADXS-HER2. The safety and efficacy of ADXS-HER2 is currently being evaluated in an ongoing Phase 1/2 veterinary clinical study in pet dogs with osteosarcoma, conducted by Nicola Mason, BVet.Med, Ph.D., DACVIM, of the University of Pennsylvania School of Veterinary Medicine. To date, dogs treated (n=15) with ADXS-HER2 immunotherapy, after receiving standard of care (amputation and follow up chemotherapy), had a statistically significant overall survival benefit (p=0.032) compared to dogs (n=13) that only received standard of care. Additionally, the preliminary data suggests immune responses induced by ADXS-HER2 targeted pulmonary micrometastases and prevent the development of metastatic disease in the dog's lungs.

Advaxis, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-19-2015 03:00 PM

Advaxis, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-19-2015 03:00 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: David J. Mauro, Chief Medical Officer and Executive Vice President.

Advaxis Enters Clinical Trial Collaboration Agreement with GOG Foundation

Advaxis said it's entering a clinical trial collaboration agreement with GOG Foundation, to evaluate the safety and efficacy of the company's lead cancer immunotherapy, ADXS-HPV, in a global Phase 3 cervical cancer trial. ADXS-HPV is an investigational Lm-LLO immunotherapy bioengineered to generate an immune response to the HPV-associated tumor specific oncogene. Prior to commencing this study, Advaxis will discuss the proposed Phase 3 program with the U.S. Food and Drug Administration and will update its investigational new drug (IND) submission. The FDA may request additional information and Advaxis said it will work expeditiously to respond to any such requests. Advaxis also plans to request a Special Protocol Assessment from the FDA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXS:US $10.05 USD -0.093

ADXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $17.03 USD -0.07
Eurocine Vaccines AB kr12.50 SEK +0.15
Genocea Biosciences Inc $8.48 USD -0.1099
GenVec Inc $3.36 USD +0.0701
Inovio Pharmaceuticals Inc $8.36 USD -0.1399
View Industry Companies
 

Industry Analysis

ADXS

Industry Average

Valuation ADXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 198.2x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 222.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVAXIS INC, please visit www.advaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.